JP2021534184A5 - - Google Patents

Info

Publication number
JP2021534184A5
JP2021534184A5 JP2021507917A JP2021507917A JP2021534184A5 JP 2021534184 A5 JP2021534184 A5 JP 2021534184A5 JP 2021507917 A JP2021507917 A JP 2021507917A JP 2021507917 A JP2021507917 A JP 2021507917A JP 2021534184 A5 JP2021534184 A5 JP 2021534184A5
Authority
JP
Japan
Prior art keywords
seq
exist
composition according
pharmaceutical composition
exists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534184A (ja
JP7483684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046698 external-priority patent/WO2020037146A1/en
Publication of JP2021534184A publication Critical patent/JP2021534184A/ja
Publication of JP2021534184A5 publication Critical patent/JP2021534184A5/ja
Priority to JP2024074284A priority Critical patent/JP7822065B2/ja
Application granted granted Critical
Publication of JP7483684B2 publication Critical patent/JP7483684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507917A 2018-08-17 2019-08-15 急性肺損傷の処置のための組成物および方法 Active JP7483684B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074284A JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
US62/719,217 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074284A Division JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021534184A JP2021534184A (ja) 2021-12-09
JP2021534184A5 true JP2021534184A5 (cg-RX-API-DMAC7.html) 2022-08-19
JP7483684B2 JP7483684B2 (ja) 2024-05-15

Family

ID=69524874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507917A Active JP7483684B2 (ja) 2018-08-17 2019-08-15 急性肺損傷の処置のための組成物および方法
JP2024074284A Active JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074284A Active JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Country Status (11)

Country Link
US (2) US12070483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836953A4 (cg-RX-API-DMAC7.html)
JP (2) JP7483684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046698A (cg-RX-API-DMAC7.html)
CN (1) CN112703009B (cg-RX-API-DMAC7.html)
AU (1) AU2019321654B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021002920A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109798A1 (cg-RX-API-DMAC7.html)
IL (1) IL280868B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021001877A (cg-RX-API-DMAC7.html)
WO (1) WO2020037146A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
EP4720090A1 (en) * 2023-05-26 2026-04-08 The Trustees of The University of Pennsylvania Protective agent against endothelial dysfunction

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001278864A1 (en) * 2000-06-30 2002-01-30 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
WO2011157819A2 (en) * 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
US11110152B2 (en) * 2016-04-11 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法

Similar Documents

Publication Publication Date Title
RU2129562C1 (ru) Производные циклических пептидов или их фармацевтически приемлемые соли, способ получения, фармацевтическая композиция
JP2019194251A5 (cg-RX-API-DMAC7.html)
JP2019196370A5 (cg-RX-API-DMAC7.html)
JP2013543501A5 (cg-RX-API-DMAC7.html)
EP1098906B1 (en) Peptide analogues of pacap
JP2006514024A5 (cg-RX-API-DMAC7.html)
WO1996012736A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FILAMENT FORMATION AND NEUROTOXICITY
RU98123833A (ru) Способы и композиции, используемые для ингибирования ангиогенеза
JP2010500399A5 (cg-RX-API-DMAC7.html)
JP2003509020A5 (cg-RX-API-DMAC7.html)
JP2011500814A5 (cg-RX-API-DMAC7.html)
JP2008521840A5 (cg-RX-API-DMAC7.html)
JP2023500248A5 (cg-RX-API-DMAC7.html)
JP2006508039A5 (cg-RX-API-DMAC7.html)
JP2002521468A5 (cg-RX-API-DMAC7.html)
JP2023524911A5 (cg-RX-API-DMAC7.html)
RU2012157399A (ru) Пептиды в качестве активных агентов для стабилизации биологических барьеров
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
FI3773664T3 (fi) Syklosporiiniformulaatioita käytettäväksi tukkeavan bronkioliittioireyhtymän (bos) hoitamisessa
JP2024537297A5 (cg-RX-API-DMAC7.html)
JP2023536132A (ja) 特発性肺線維症の予防または治療用ポリペプチド及びそれらを含む医薬組成物
JP2004506017A (ja) 抗真菌剤組合せ使用
JP2023544409A5 (cg-RX-API-DMAC7.html)
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
JP2015514771A5 (cg-RX-API-DMAC7.html)